The Africa Centres for Disease Control and Prevention (Africa CDC) has explained why vaccines are not yet available for the Bundibugyo strain of Ebola, as the agency announces clinical trials of new vaccine candidates.
Speaking during an interview on Channels Television’s The Morning Brief on Thursday, October 22, 2026, Africa CDC Director-General, Dr Jean Kaseya, said the lack of available vaccines reflected what he described as insufficient international commitment to addressing health emergencies in Africa.
Kaseya alleged that some international partners regard Ebola as primarily an African problem, suggesting that the response would be different if an outbreak occurred in Western countries.
“If this outbreak was in Western countries, vaccines would already be available,” he said.
Despite the absence of an approved vaccine for the Bundibugyo strain, Kaseya said the Africa CDC had initiated clinical trials of new vaccine candidates.
He disclosed that the candidates include a new vaccine against the Bundibugyo strain manufactured in Egypt.
The development comes amid heightened attention to Ebola following a reported case in Nigeria involving a Ugandan-born patient who arrived in Abuja on October 3, according to a separate report by Channels Television.
The Nigerian government and health authorities have also announced measures in response to the case, including restrictions affecting identified contacts and efforts to strengthen containment.
Ebola is a serious infectious disease that can cause severe illness and death. Different Ebola virus species exist, and vaccines developed for one species do not necessarily provide protection against another.
The Bundibugyo virus is one of the species responsible for Ebola disease. The development of vaccines specifically targeting this strain remains an important part of efforts to improve preparedness for future outbreaks.
The Africa CDC’s announcement of clinical trials signals progress towards expanding vaccine options, although trial results and regulatory approval would be needed before a new vaccine could become widely available.